Twist Bioscience upgraded at Evercore ISI with accounting fears eased

As previously reported, Evercore ISI analyst Vijay Kumar upgraded Twist Bioscience to Outperform from In Line with a price target of $36, up from $28. Management has allayed fears around accounting issues raised by the bears and he believes "the tides are changing," Kumar tells investors. Twist has given "realistic outyear targets" and provided conviction around working towards adjusted EBITDA breakeven, the analyst added.